---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-292703"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:40:33.001583+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# AADI Bioscience regains compliance with Nasdaq audit committee independence rule

## Summary
- Non-compliance resulted from Dr. Karin Hehenberger not qualifying as independent per Nasdaq Listing Rule 5605(c)(2)(A).
- Board removed Hehenberger from Audit Committee and appointed Caley Castelein, M.D., who meets independence requirements.
- Audit Committee now consists of Emma Reeve (chair), Richard Maroun, and Caley Castelein; company believes compliance restored.

## SEC filing metadata
- accession: 0001193125-22-292703
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312522292703/0001193125-22-292703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312522292703/d425406d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-292703
- JSON: https://secwatch.observer/filing/0001193125-22-292703.json
- Plain text: https://secwatch.observer/filing/0001193125-22-292703.txt

## Key facts
- Listing & Compliance Notices
  Whitehawk Therapeutics, Inc. received a nasdaq compliance regained notice regarding audit committee (rules 5605(c)(2)(A)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: audit committee
  - Rules: 5605(c)(2)(A)
  source text: November 23, 2022, Aadi Bioscience, Inc. (the “Company”) notified The Nasdaq Stock Market LLC (“Nasdaq”) of the Company’s non-compliance with Nasdaq’s audit committee composition requirements set forth in Nasdaq Listing Rule 5605(c)(2)(A), which require, among other things, an audit committee to consist of at least three members, each of whom is independent. The non-compliance was a result of Karin Hehenberger, M.D., Ph.D., a member of the Audit Committee (the “Audit Committee”) of the board of directors of the Company (the “Board”), not qualifying as independent pursuant to Nasdaq Listing Rul
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312522292703/0001193125-22-292703-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.